BioSpace News Archive

Visit booth 4631 to see disposable and sterile needles for the delivery of anesthetic

ObsEva SA announced that the U.S. Food and Drug Administration has allowed the Company to begin enrolling patients in IMPLANT 3, the U.S pivotal Phase 3 clinical trial of nolasiban in women undergoing embryo transfer following in-vitro fertilization.

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it will present new data on the safety and efficacy of the company’s lead investigational candidate, AR101 (trade name Palforzia™), at the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting, taking place November 7-11, 2019, in Houston

Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease (ESRD), today announced the appointment of John P. McLaughlin as its Chairman of the Board, effective immediately. Mr. McLaughlin, who joined the Board on September 5, 2019, succeeds Benjamin Wolin, who will remain on the Board of Directors.

The Company invites you to listen to the call by dialing (866) 393-8366. International participants should call (409) 350-3154.

Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq:BBIO), today reported its financial results for the third quarter ended September 30, 2019 and provided an update on the company’s recent achievements, upcoming events and chief financial officer transition plan.

Flexion’s management will host a conference call at 4:30 p.m. ET to discuss the results and provide an update on business operations.

Third-quarter 2019 net sales were $560.6 million, an increase of 2.8 percent compared to $545.1 million reported for the third quarter of 2018.

Findings and Recommendations Intended to Inform Master Settlement Negotiators, Congress, and Other Federal, State, and Local Policy Makers

Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results